Longitudinal survey of carbapenem resistance and resistance mechanisms in enterobacteriaceae and non-fermenters from the USA in 2007-09

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2298-2307

  Davies, Todd A ^a   Marie queenan, Anne ^a   Morrow, Brian J ^a   Shang, Wenchi ^a   Amsler, Karen ^a   He, Wenping ^a   Lynch, A Simon ^a   Pillar, Chris ^b   Flamm, Robert K ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Acinetobacter baumannii; Doripenem; Klebsiella pneumoniae; Pseudomonas aeruginosa; Surveillance

Indexed keywords

BETA LACTAMASE AMPC; CARBAPENEM; CEFTAZIDIME; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENOTYPE; INCIDENCE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNITED STATES; UPREGULATION; WESTERN BLOTTING;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; GENOTYPE; IMIPENEM; KLEBSIELLA PNEUMONIAE; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; PORINS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; UNITED STATES;

EID: 80052898593     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr290     Document Type: Article

References (61)

1. Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009; 65: 414-26.
2. Ortho-McNeil-Janssen Pharmaceuticals, Inc.Doribax (Doripenem for Injection) Full Prescribing Information. http://www.doribax.com/interactive_pi.html (31 May 2011, date last accessed).
3. Doribax European summary of product characteristics (EU SMPC). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_ Information/human/000891/WC500037148.pdf (31 May 2011, date last accessed).
4. Kaniga K, Flamm R, Tong S-Y et al. Worldwide experience with the use of doripenem against extended-spectrum-β-lactamaseproducing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010; 54: 2119-24.
5. Pillar CM, Torres MK, Brown NP et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging gram-negative infections, against recent US clinical isolates. Antimicrob Agents Chemother 2008; 52: 4388-99.
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically- Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2008.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
8. Mesaros N, Glupczynski Y, Avrain L et al. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 2007; 59: 378-86.
9. Pannek S, Higgins PG, Steinke P et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-b-naphthylamide. J Antimicrob Chemother 2006; 57: 970-4.
10. Higgins PG, Wisplinghoff H, Stefanik D et al. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004; 54: 821-3.
11. Mendes RE, Kiyota KA, Monteiro J et al. Rapid detection and identification of metallo-β-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol 2007; 45: 544-7.
12. Woodford N, Ellington MJ, Coelho JM et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006; 27: 351-3.
13. Cole JM, Schuetz AN, Hill CE et al. Development and evaluation of a real-time PCR assay for detection of Klebsiella pneumoniae carbapenemase genes. J Clin Microbiol 2009; 47: 322-6.
14. Hu WS, Yao S-M, Fung C-P et al. An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3844-52.
15. Matthew M, Harris AM. Identification of β-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy. J Gen Microbiol 1976; 94: 55-67.
16. Soge OO, Queenan AM, Ojo KK et al. CTX-M-15 extended-spectrum β-lactamase from Nigerian Klebsiella pneumoniae. J Antimicrob Chemother 2006; 57: 24-30.
17. Carlone GM, Thomas ML, Rumschlag HS et al. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. J Clin Microbiol 1986; 24: 330-2.
18. Klebsiellla pneumoniae MLST database. http:www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html (8 February 2011, date last accessed).
19. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other non-fermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63: 426-33.
20. Livermore DM, Hope R, Brick G et al. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii55-63.
21. Doumith M, Ellington MJ, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp.: clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67.
22. Kitchel B, Rasheed JK, Endimiani A et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54: 4201-7.
23. Yang Q, Wang H, Sun H et al. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother 2010; 54: 573-7.
24. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008; 61: 203-13.
25. Rhomberg PR, Deshpande LM, Kirby JT et al. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn Microbiol Infect Dis 2007; 59: 425-32.
26. Bogaerts P, Montesinos I, Rodriguez-Villalobos H et al. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing KPC-2 carbapenemase in Belgium. J Antimicrob Chemother 2010; 65: 361-2.
27. Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53: 3365-70.
28. Leavitt A, Carmeli Y, Chmelnitsky I et al. Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. Antimicrob Agents Chemother 2010; 54: 3002-6.
29. Bratu S, Mooty M, Nichani S et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49: 3018-20.
30. Endimiani A, Hujer AM, Perez F et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009; 63: 427-37.
31. Kitchel B, Sundin DR, Patel JB. Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2009; 53: 4511-3.
32. Woodford N, Tierno PM Jr, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem- hydrolyzing class a β-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004; 48: 4793-9.
33. Deshpande LM, Rhomberg PR, Sader HS et al. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999-2005). Diagn Microbiol Infect Dis 2006; 56: 367-72.
34. CDC. Detection of Enterobacteriaceae isolates carrying metallo-β-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 750.
35. Karthikeyan KK, Mark AT, Timothy RW et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
36. Castanheira M, Sader HS, Deshpande LM et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008; 52: 570-3.
37. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007; 20: 440-58.
38. Coban AY, Tanriverdi Cayci Y, Erturan Z et al. Effects of efflux pump inhibitors phenyl-arginine-b-naphthylamide and 1-(1-naphthylmethyl)-piperazine on the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Chemotherapy 2009; 21: 592-4.
39. Masuda N, Sakagawa E, Ohya S et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-7.
40. Farra A, Islam S, Strålfors A et al. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents 2008; 31: 427-33.
41. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-50.
42. Pai H, Kim J-W, Kim J et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45: 480-4.
43. Zavascki AP, Carvalhaes CG, Picao RC et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti-infective Ther 2010; 8: 71-93.
44. Poirel L, Nordmann P, Lagrutta E et al. Emergence of KPC-producing Pseudomonas aeruginosa in the United States. Antimicrob Agents Chemother 2010; 54: 3072.
45. Wolter DJ, Khalaf N, Robledo IE et al. Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican medical center hospitals: dissemination of KPC and IMP-18 β-lactamases. Antimicrob Agents Chemother 2009; 53: 1660-4.
46. Walsh TR, Toleman MA, Poirel L et al. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
47. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 1210-5.
48. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45: 3375-80.
49. Bratu S, Landman D, Martin DA et al. Correlation of antimicrobial resistance with β-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother 2008; 52: 2999-3005.
50. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: S49-56.
51. Higgins PG, Dammhayn C, Hackel M et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8.
52. Turton JF, Ward ME,Woodford N et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006; 258: 72-7.
53. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-36.
54. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Micro 2007; 5: 939-51.
55. Perez F, Endimiani A, Ray AJ et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010; 65: 1807-18.
56. Bou G, Martinez-Beltran J. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2000; 44: 428-32.
57. Quale J, Bratu S, Landman D et al. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37: 214-20.
58. Dupont M, Pages J-M, Lafitte D et al. Identification of an OprD homologue in Acinetobacter baumannii. J Proteome Res 2005; 4: 2386-90.
59. Mussi MA, Relling VM, Limansky AS et al. CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for L-ornithine uptake. FEBS Lett 2007; 581: 5573-8.
60. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC et al. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51: 565-74.
61. Urban C, Go E, Mariano N et al. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiol Lett 1995; 125: 193-7.